{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:17:43Z","timestamp":1787494663535,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.iotech.2026.101598","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:43:02Z","timestamp":1780706582000},"page":"101598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4923-0680","authenticated-orcid":false,"given":"P.","family":"Mei\u00dfner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-497X","authenticated-orcid":false,"given":"P.","family":"Kaps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Momper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3348-8005","authenticated-orcid":false,"given":"A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Raabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"Strueder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Langenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brandstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-2986","authenticated-orcid":false,"given":"A.S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zimpfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-8439","authenticated-orcid":false,"given":"C.","family":"Maletzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2026.101598_bib1","first-page":"1","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","author":"Filho","year":"2024","journal-title":"Int J cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101598_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011929","article-title":"SITC vision: opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy","volume":"13","author":"Sullivan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.iotech.2026.101598_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.iotech.2026.101598_bib6","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.iotech.2026.101598_bib7","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1158\/2159-8290.CD-22-0851","article-title":"Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T-cell and activated treg compartment","volume":"13","author":"van der Leun","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.iotech.2026.101598_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-18-1522","article-title":"Oral mucosal organoids as a potential platform for personalized cancer therapy","volume":"9","author":"Driehuis","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.iotech.2026.101598_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.medj.2023.04.003","article-title":"Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification","volume":"4","author":"Millen","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.iotech.2026.101598_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107742","article-title":"Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as a novel alternative model for drug response in head and neck cancer","volume":"171","author":"Doerfler","year":"2025","journal-title":"Oral Oncol"},{"key":"10.1016\/j.iotech.2026.101598_bib11","first-page":"1","article-title":"Generating tumor-specific T cells based on a head and neck cancer organoid for adoptive cell therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101598_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115100","article-title":"Feasibility analysis of using patient-derived tumour organoids for treatment decision guidance in locally advanced head and neck squamous cell carcinoma","volume":"213","author":"Fisch","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70129","article-title":"The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma","volume":"13","author":"Wong","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.iotech.2026.101598_bib14","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101598_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101598_bib16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.iotech.2026.101598_bib17","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101598_bib18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.stem.2025.05.011","article-title":"An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer","volume":"32","author":"Li","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.iotech.2026.101598_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13046-021-02047-w","article-title":"Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies","volume":"40","author":"Str\u00fcder","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101598_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","article-title":"Tumor organoid\u2013T-cell coculture systems","volume":"15","author":"Cattaneo","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.iotech.2026.101598_bib21","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications","volume":"15","author":"Driehuis","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.iotech.2026.101598_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cpsc.109","article-title":"Generation and characterization of patient-derived head and neck, oral, and esophageal cancer organoids","volume":"53","author":"Karakasheva","year":"2020","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"10.1016\/j.iotech.2026.101598_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.stem.2025.05.009","article-title":"Prioritizing human tissue research: Q&A with Danilo Tagle","volume":"32","author":"Tagle","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.iotech.2026.101598_bib24","article-title":"Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy","volume":"15","author":"Romero","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.iotech.2026.101598_bib25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13287-025-04599-6","article-title":"Head and neck cancer organoids: a panoramic perspective from basic construction to clinical translation","volume":"16","author":"Meng","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.iotech.2026.101598_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/cpsc.109","article-title":"Generation and characterization of patient-derived head and neck, oral, and esophageal cancer organoids","volume":"53","author":"Karakasheva","year":"2020","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"10.1016\/j.iotech.2026.101598_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.oraloncology.2018.10.018","article-title":"Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity","volume":"87","author":"Tanaka","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.iotech.2026.101598_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10692-x","article-title":"ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies","volume":"23","author":"Perr\u00e9ard","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib29","article-title":"Generating tumor-specific T cells based on a head and neck cancer organoid for adoptive cell therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101598_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/imcb.70043","article-title":"Th17 cells in cancer: plasticity-driven immunopathology and therapeutic opportunity","volume":"103","author":"Sutanto","year":"2025","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.iotech.2026.101598_bib31","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/eji.202049119","article-title":"Evolved to protect, designed to destroy: IL-17-producing \u03b3\u03b4 T cells in infection, inflammation, and cancer","volume":"51","author":"Agerholm","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.iotech.2026.101598_bib32","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3892\/or.2017.5426","article-title":"Interleukin-17A promotes esophageal adenocarcinoma cell invasiveness through ROS-dependent, NF-\u03baB-mediated MMP-2\/9 activation","volume":"37","author":"Liu","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.iotech.2026.101598_bib33","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101598_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2477872","article-title":"Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model","volume":"14","author":"Lamenza","year":"2025","journal-title":"Oncoimmunol"},{"key":"10.1016\/j.iotech.2026.101598_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1604","article-title":"Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells","volume":"14","author":"Neuhaus","year":"2024","journal-title":"Clin Transl Med"},{"issue":"10","key":"10.1016\/j.iotech.2026.101598_bib36","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s43018-025-01007-z","article-title":"IL-17A-secreting \u03b3\u03b4 T cells promote resistance to CDK4\/CDK6 inhibitors in HR+HER2\u2212breast cancer via CX3CR1+ macrophages","volume":"6","author":"Petroni","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04365-3","article-title":"IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer","volume":"21","author":"Liao","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.iotech.2026.101598_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.900273","article-title":"Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101598_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22875-w","article-title":"Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS\/p53 mutant lung cancers","volume":"12","author":"Peng","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.iotech.2026.101598_bib40","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","article-title":"Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma","volume":"4","author":"V\u00e1raljai","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70442","article-title":"The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenocarcinoma","volume":"15","author":"Tiberi","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.iotech.2026.101598_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188758","article-title":"Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.iotech.2026.101598_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-022-02703-1","article-title":"Prognostic biomarker IL17A correlated with immune infiltrates in head and neck cancer","volume":"20","author":"Yu","year":"2022","journal-title":"World J Surg Oncol"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:02:41Z","timestamp":1781870561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S2590018826000171"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101598","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101598"}}